Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 97,605 shares, a decline of 35.1% from the September 30th total of 150,336 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 119,437 shares, the days-to-cover ratio is presently 0.8 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Decoy Therapeutics in a research note on Wednesday, September 9th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.00.
Get Our Latest Analysis on DCOY
Decoy Therapeutics Trading Down 3.3%
DCOY opened at $1.03 on Tuesday. The company has a market cap of $2.47 million, a P/E ratio of -0.03 and a beta of 0.65. The business’s 50-day moving average price is $2.12 and its 200-day moving average price is $5.37. Decoy Therapeutics has a 12 month low of $0.90 and a 12 month high of $47.16.
Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($4.46) earnings per share for the quarter. The company had revenue of $0.23 million during the quarter. Equities research analysts forecast that Decoy Therapeutics will post -8.96 earnings per share for the current fiscal year.
About Decoy Therapeutics
Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms.
The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.
Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited.
Further Reading
- Five stocks we like better than Decoy Therapeutics
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
